文献速递主动脉疾病

胸主动脉腔内修复对急性非复杂性B型主动脉夹层患者生存的有利影响

Favorable impact of thoracic endovascular aortic repair on survival of patients with acute uncomplicated type B aortic dissection.
PubMed 文献 · J Vasc Surg · 2018-06-15

基于加利福尼亚州2000至2010年数据库分析9165例急性非复杂性B型主动脉夹层患者,比较药物治疗、开放手术和胸主动脉腔内修复(TEVAR)的长期生存。TEVAR较药物治疗有独立生存优势(HR 0.68,95%CI 0.6-0.8),开放手术与药物治疗无差异。

要点

  • 急性非复杂性B型主动脉夹层中,TEVAR较药物治疗有独立生存优势(HR 0.68,95%CI 0.6-0.8)。
  • 开放手术与药物治疗的长期生存无差异(HR 1.0,95%CI 0.8-1.3)。
  • TEVAR的1年和5年生存率分别为85%和76%,高于药物治疗的84%和60%。

核心结论

  • 全州范围研究显示,急性非复杂性B型主动脉夹层中TEVAR较药物治疗具有独立生存优势,这些数据为B型夹层急性期管理向早期TEVAR转变提供了进一步证据。

研究设计与样本

  • 分析加利福尼亚州医院规划发展办公室数据库2000至2010年成人急性非复杂性B型主动脉夹层患者,按索引入院时治疗方式分为药物治疗、开放手术修复和TEVAR三组,采用多变量回归和生存分析评估治疗方式与长期总生存的关联。

主要发现

  • 共9165例,药物治疗占95%,开放修复占2%,TEVAR占2.9%;平均年龄66±15岁,女性39%,可卡因使用者2.4%,充血性心力衰竭18%,Charlson合并症指数>3者17%。
  • 平均住院费用:药物治疗57000美元,开放修复200000美元,TEVAR 130000美元(P < .01)。
  • 住院死亡率总体6.5%,药物治疗6.3%,开放修复14%,TEVAR 7.1%(P < .01)。
  • 1年和5年生存率:药物治疗84%和60%,开放修复76%和67%,TEVAR 85%和76%(log-rank,P < .01)。
  • 风险调整多变量分析中,TEVAR较药物治疗生存改善(HR 0.68,95%CI 0.6-0.8,P < .01),开放修复与药物治疗无差异(HR 1.0,95%CI 0.8-1.3,P < .01)。

临床怎么用

  • 作者认为这些数据为B型夹层急性期管理向早期TEVAR转变提供了进一步证据。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In uncomplicated type B aortic dissection (UTBAD), the "gold standard" has been nonoperative treatment with medical therapy, although this has been questioned by studies demonstrating improved outcomes in those treated with thoracic endovascular aortic repair (TEVAR). This study assessed long-term survival after acute UTBAD comparing medical therapy, open repair, and TEVAR. METHODS: The California Office of Statewide Hospital Planning Development database was analyzed from 2000 to 2010 for adult patients with acute UTBAD. Patients with nonemergent admission for aortic dissection, type A dissection, trauma, bowel ischemia, lower extremity ischemia, acidosis, or shock were excluded. The cohort was stratified by treatment type at index admission into medical therapy, open surgical repair, and TEVAR. Multivariable regression and survival analyses were used to evaluate the association of treatment type with long-term overall survival. RESULTS: There were 9165 cases, 95% medical therapy, 2% open repair, and 2.9% TEVAR. The mean age was 66 ± 15 years, with 39% female, 2.4% cocaine users, 18% with congestive heart failure, and 17% with Charlson Comorbidity Index >3. Mean inpatient costs were $57,000 for medical therapy, $200,000 for open repair, and $130,000 for TEVAR (P < .01). Inpatient mortality was 6.5% overall, 6.3% for medical therapy, 14% for open repair, and 7.1% for TEVAR (P < .01). One-year and 5-year survivals were 84% and 60% in medical therapy, 76% and 67% in open repair, and 85% and 76% in TEVAR (log-rank, P < .01). On risk-adjusted multivariable analysis, TEVAR had improved survival compared with medical therapy (hazard ratio, 0.68; 95% confidence interval, 0.6-0.8; P < .01), with no difference between open repair and medical therapy (hazard ratio, 1.0; 95% confidence interval, 0.8-1.3; P < .01). CONCLUSIONS: This statewide study on survival after acute UTBADs shows an independent survival advantage for TEVAR over medical therapy. These data add further evidence for a paradigm shift in acute management of type B dissection in favor of early TEVAR.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Iannuzzi JC, Stapleton SM, Bababekov YJ, et al. Favorable impact of thoracic endovascular aortic repair on survival of patients with acute uncomplicated type B aortic dissection. J Vasc Surg. 2018. PMID: 29914833. doi:10.1016/j.jvs.2018.04.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。